This post may contain affiliate links.

A Brief History of the COVID-19 Vaccine

A Brief History of the mRNA COVID-19 Vaccine

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has affected millions of people worldwide since first emerging in late 2019. Governments, scientists, and pharmaceutical companies have been working together to develop a vaccine that could prevent the spread of the virus and help end the pandemic. The COVID-19 vaccine is a new type of vaccine that uses RNA technology, and its development has been a remarkable achievement in the history of medicine.

A wide range of symptoms, which can vary in severity from mild to severe or even life-threatening, can occur with a COVID-19 infection. The most common symptoms include fever, cough, fatigue, and shortness of breath, which may appear two to fourteen days after exposure to the virus. Other symptoms may include loss of taste or smell, sore throat, congestion or runny nose, body aches, headache, nausea, vomiting, and diarrhea. Some people with COVID-19 may also experience more serious complications such as pneumonia, acute respiratory distress syndrome (ARDS), sepsis, or multi-organ failure, which can be fatal in some cases. The severity of symptoms can vary depending on age, underlying health conditions, and immune system response.

History of the COVID-19 Vaccine

The development of the COVID-19 vaccine started in early 2020 shortly after the virus was identified. The first vaccine to receive emergency use authorization in the United States was the Pfizer-BioNTech vaccine, which was authorized in December 2020. The Moderna vaccine was authorized shortly after in December 2020. These vaccines use a new type of technology, called messenger RNA (mRNA), to train the immune system to recognize and fight the virus.

Despite being studied for many years, mRNA vaccine technology had never been used before in humans. mRNA vaccines work by using a small piece of genetic material called messenger RNA (mRNA) that contains instructions for making a protein that triggers an immune response to the SARS-CoV-2 virus. In the case of COVID-19 vaccines, the mRNA instructs cells to produce a piece of the spike protein found on the surface of the SARS-CoV-2 virus. This spike protein is what the virus uses to enter human cells and cause infection.


When injected into the body, mRNA enters cells and uses the cell to make copies of the spike protein. These spike proteins are then displayed on the surface of the cells, which triggers an immune response. The immune system recognizes the spike protein as foreign and produces antibodies to neutralize it. If the person is exposed to the actual virus later on, their immune system will recognize and attack the virus based on the memory of the spike protein.

One advantage of using mRNA vaccines is that they can be developed and manufactured more quickly than traditional vaccines, as the genetic code for the spike protein can be determined rapidly and the mRNA can be synthesized in the laboratory. Additionally, mRNA vaccines do not contain live virus particles and do not require adjuvants or preservatives, which can make them safer and more tolerable for some people.

History of mRNA Vaccines


The development of mRNA vaccines started in the 1990s when researchers first identified the potential of using mRNA as a vaccine platform. The idea was that, by using mRNA to instruct cells to produce specific proteins, the immune system could be trained to recognize and fight diseases. However, mRNA technology faced many challenges including how to deliver the mRNA molecules into cells and how to prevent the body from attacking the mRNA as a foreign invader.

Over the years, advances in technology and a better understanding of the immune system helped overcome these challenges. In 2005, scientists at the University of Pennsylvania used mRNA to produce a vaccine against the flu virus in mice. The vaccine was able to induce an immune response, and the mice were protected against the flu virus.

In the following years, researchers continued to study and refine mRNA vaccine technology. In 2013, the company BioNTech was founded with a focus on developing personalized cancer vaccines using mRNA. BioNTech teamed up with the pharmaceutical company Pfizer in 2018 to work on developing mRNA vaccines for a variety of infectious diseases.

Development of the COVID-19 Vaccine

When the COVID-19 pandemic began in early 2020, researchers and pharmaceutical companies turned their attention to developing a vaccine to prevent the spread of the virus. Because the virus was so new, researchers had to work quickly to identify the specific genetic sequence of the virus and develop a vaccine that could be effective against it.

BioNTech and Pfizer were among the first to develop an mRNA vaccine for COVID-19. The vaccine, called BNT162b2, was developed using a new type of mRNA technology that had been studied for many years. The vaccine was tested in clinical trials, and the results showed that it was highly effective at preventing COVID-19.

Moderna also developed an mRNA vaccine for COVID-19, which was authorized for emergency use in December 2020. The Moderna vaccine, like the Pfizer-BioNTech vaccine, uses mRNA technology to train the immune system to recognize and fight the virus. These vaccines have been shown to be highly effective at preventing COVID-19 infection in clinical trials, with efficacy rates of around 95%. However, as with any vaccine, there may be some side effects, such as pain at the injection site, fatigue, headache, and fever, although these are generally mild and short-lived.

Other vaccines, such as the Johnson & Johnson vaccine and the AstraZeneca vaccine, use a different technology called viral vector vaccines. These vaccines use a harmless virus, such as an adenovirus, to carry genetic material from the SARS-CoV-2 virus into cells, which then triggers an immune response. These vaccines have also been shown to be effective at preventing COVID-19.

Distribution of the COVID-19 Vaccine

The distribution of the COVID-19 vaccine has been a complex and challenging process. Governments and health organizations around the world have had to coordinate the manufacturing, distribution, and administration of the vaccine to millions of people. Some challenges have arisen such vaccine hesitancy, supply chain issues, and the equitable distribution of the vaccine.

One of the challenges with the distribution of the COVID-19 vaccine has been the need for ultra-cold storage. The mRNA vaccines developed by Pfizer-BioNTech and Moderna need to be stored at very low temperatures, which has made distribution more difficult. However, new technologies, such as special refrigeration units and dry ice, have helped make distribution easier.

Future of the COVID-19 Vaccine

A remarkable achievement in the history of medicine, the COVID-19 vaccine has provided hope and protection to millions of people around the world. However, the pandemic is not over, and many challenges still lie ahead.

One of the biggest challenges is the emergence of new variants of the virus. The virus is constantly evolving, and new variants have been identified that may be more transmissible or more resistant to the vaccine. The emergence of new variants highlights the need for ongoing research and development of new vaccines and treatments.

The pharmaceutical companies that developed the COVID-19 vaccine are already working on developing booster shots that could provide additional protection against new variants of the virus. Booster shots are additional doses of the vaccine that are given after the initial dose. Booster shots have been used in the past to increase the effectiveness of vaccines, and they may be necessary to provide ongoing protection against COVID-19.

Another challenge is vaccine hesitancy. Some people are hesitant to get the vaccine, either because they are concerned about side effects or because they do not believe that the vaccine is effective. Vaccine hesitancy has the potential to slow down the progress of the pandemic and make it more difficult to achieve herd immunity.


The development of the COVID-19 vaccine has been a remarkable achievement in the history of medicine. The vaccine was developed in record time using a new type of technology, mRNA. The mRNA technology had been studied for many years and has the potential to revolutionize the field of vaccine development.

The distribution of the vaccine has been challenging, but new technologies and innovative solutions have helped make it possible to get the vaccine to millions of people around the world. However, the pandemic is not over. Many challenges associated with COVID-19 continue including the emergence of new variants and vaccine hesitancy.

The future of the COVID-19 vaccine is promising. The development of booster shots and ongoing research into new vaccines and treatments will help to provide ongoing protection against the virus. The COVID-19 pandemic has shown the importance of science, innovation, and collaboration in the face of a global crisis.


Baden, L. R., El Sahly, H. M., Essink, B., et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384(5), 403-416.
BBC News. (2021, March 15). Covid: What do we know about the AstraZeneca vaccine?
Centers for Disease Control and Prevention. (2021). COVID-19 vaccines.
The Guardian. (2021, March 16). Sinovac: the Covid vaccine that’s getting global approval despite controversy.
Jackson, L. A., Anderson, E. J., Rouphael, N. G., et al. (2020). An mRNA vaccine against SARS-CoV-2 – Preliminary report. New England Journal of Medicine, 383(20), 1920-1931.
Moderna. (2021). Moderna COVID-19 vaccine.
National Institutes of Health. (2020). COVID-19 treatment guidelines.
New York Times. (2021, February 1). Johnson & Johnson single-dose Covid-19 vaccine is shown to be effective.
Polack, F. P., Thomas, S. J., Kitchin, N., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615.
Pfizer-BioNTech. (2021). Pfizer-BioNTech COVID-19 vaccine.
Reuters. (2021, January 26). Novavax vaccine 89% effective in UK trials, less so against South African variant.
Voysey, M., Clemens, S. A. C., Madhi, S. A., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.
World Health Organization. (2020). WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020.—11-march-2020

Image Credits

A Brief History of the mRNA COVID-19 Vaccine © 2023 The Parenting Patch
COVID-19 Vaccine Vial:
Moderna COVID-19 Vaccine:

A Brief History of the COVID-19 Vaccine